Accuray (NASDAQ:ARAY) Azioni

Accuray

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Accuray Inc

SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatment sessions, with the goal of ablating (destroying) the tumor or lesion. To achieve the accuracy and precision required, the CyberKnife System uses image guidance during treatment, and leverages potentially 1,000 different beam angles targeting the tumor as well as Synchrony&#xAE; adaptive delivery, which adjusts the aim of the beam in real time to correct for tumor or patient motion.
"The studies presented at this year's Radiosurgery Society meeting underscore both the long-term efficacy and expanding applications of the CyberKnife System. Whether treating benign tumors like vestibular schwannoma or managing complex conditions such as spinal metastases and trigeminal neuralgia, the common thread is the need for precise, highly targeted radiation delivery — a hallmark of the CyberKnife System. These new data not only reinforce its value in central nervous system treatments but also add to the growing body of evidence supporting its role in improving both the quality and longevity of patients' lives," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray.
RSS CyberKnife System Study Highlights: Advancing and Expanding Patient Care
25-Year Data Supports the Use of the CyberKnife System to Treat Vestibular Schwannoma (VS)
<ul>
<li>25-year data were reported for patients in a single institution study retrospectively evaluating SRS for the treatment of VS (also known as acoustic neuroma) using the CyberKnife System. A non-cancerous, usually slow-growing brain tumor, VS can cause hearing loss, ringing in the ear, and dizziness or loss of balance. The study demonstrated treatment with the system provides sustained local tumor control and long-term efficacy. At 25 years, the local control rate was 89.3 percent and overall survival was 97.1 percent 2.</li>
</ul>
Clinical Innovation Facilitates Treatment of Challenging Condition Using the CyberKnife System
<ul>
<li>A study evaluated the safety and efficacy of donut-shaped circumferential stereotactic body radiation therapy (SBRT) delivered using the CyberKnife System for the treatment of spinal metastases. This treatment technique is designed to target the spinal column while avoiding the spinal cord. High doses of radiation delivered to the spinal cord can result in serious complications, such as radiation myelopathy, causing injury or paralysis. Study investigators concluded, "Donut-shaped circumferential CyberKnife SBRT is a safe and effective treatment for spinal metastases, achieving high local tumor control with minimal radiation-induced complications, including myelopathy&nbsp;3."</li>
</ul>
CyberKnife System Expands Treatment Options for Patients with Painful Neurological Conditions Trigeminal neuralgia and occipital condyle metastasis are rare conditions often causing excruciating pain that may impact all aspects of patients' daily life.
<ul>
<li>A study of elderly patients (aged 80 to 100 years) with trigeminal neuralgia found that radiosurgery delivered using the CyberKnife System provides excellent outcomes. Pain improved or disappeared in 90 percent of those evaluated and only three percent developed paresthesia – a sensation of tingling, "pins and needles" or numbness – considered bothersome. Data indicate radiosurgery provides an option for a patient population that may have limited choices because health issues preclude surgery or they are unresponsive to medication4.</li>
<li>An evaluation of SRS for occipital condyle metastasis (OCM) using the CyberKnife System found the treatment offers significant pain relief, excellent local control rates and improvement in neurological symptoms. A 93.8 percent local tumor control rate was achieved over three years. Of patients who reported symptoms, 87.5 percent experienced pain relief. Study authors concluded, "This non-invasive therapy provides a valuable alternative to surgery, potentially enhancing the quality of life for patients with limited treatment options due to this challenging condition5."</li>
</ul>

News

Health Care

General

ARAY

Accuray Announced That New Data On The Clinical Use Of The CyberKnife System Reinforce The Device's Broad-based Radiation Treatment Capabilities For Central Nervous System Tumors

WIIM

Accuray shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance above estimates.

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) released its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04.
Revenue was up $8.94 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.01 in the last quarter, resulting in a 3.0% increase share price change the following day.
Here's a look at Accuray's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
<td>-0.10</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>97.55M</td>
<td>121.51M</td>
<td>113.65M</td>
<td>106.67M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>101.55M</td>
<td>134.29M</td>
<td>101.13M</td>
<td>107.24M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Accuray <a href="https://www.benzinga.com/quote/ARAY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Accuray Q2 Earnings Assessment

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) announced its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04.
Revenue was up $8.94 million from the same period last year.
<h3>Overview of Past Earnings</h3>
Last quarter the company beat on EPS by $0.01 which was followed by a 3.0% increase in the share price the next day.
Here's a look at Accuray's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
<td>-0.10</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>97.55M</td>
<td>121.51M</td>
<td>113.65M</td>
<td>106.67M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>101.55M</td>
<td>134.29M</td>
<td>101.13M</td>
<td>107.24M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Accuray <a href="https://www.benzinga.com/quote/ARAY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Accuray Q2 Earnings Report: What Investors Need to Know

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) released its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04.
Revenue was up $8.94 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% increase share price change the next day.
Here's a look at Accuray's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
<td>-0.10</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>97.55M</td>
<td>121.51M</td>
<td>113.65M</td>
<td>106.67M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>101.55M</td>
<td>134.29M</td>
<td>101.13M</td>
<td>107.24M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Accuray <a href="https://www.benzinga.com/quote/ARAY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Accuray Q2 Earnings Summary & Key Takeaways

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) just disclosed its Q2 earnings on Wednesday, February 5, 2025 at 04:05 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Accuray beat estimated earnings by 150.0%, reporting an EPS of $0.02 versus an estimate of $-0.04.
Revenue was up $8.94 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% increase share price change the next day.
Here's a look at Accuray's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.05</td>
<td>0.03</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.04</td>
<td>0.03</td>
<td>-0.06</td>
<td>-0.10</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>97.55M</td>
<td>121.51M</td>
<td>113.65M</td>
<td>106.67M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>101.55M</td>
<td>134.29M</td>
<td>101.13M</td>
<td>107.24M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Accuray <a href="https://www.benzinga.com/quote/ARAY/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Accuray Q2

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) raises FY2025 sales outlook from $462.00 million-472.00 million to $463.00 million-475.00 million vs $466.89 million estimate.

Guidance

Accuray Raises FY2025 Sales Guidance from $462.00M-472.00M to $463.00M-475.00M vs $466.89M Est

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.04) by 150 percent. This is a 120 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $116.17 million which beat the analyst consensus estimate of $110.36 million by 5.27 percent. This is a 8.33 percent increase over sales of $107.24 million the same period last year.

Earnings Beats

Accuray Q2 EPS $0.02 Beats $(0.04) Estimate, Sales $116.17M Beat $110.36M Estimate

ALGN

AMSC

AOSL

APPS

ARCC

ARES

ASGN

ASYS

AZTA

BARK

BLBD

BSBR

CENT

CENTA

CMRE

CNMD

CNXN

COHR

CPAY

CPRI

CRTO

CSGS

CTSH

CTVA

DGII

DLHC

ENSG

EQNR

EZPW

FORM

GEOS

HOLX

ITUB

KMPR

LFVN

LSAK

LUCK

LVWR

MSTR

MTRX

MUSA

NOTV

NTGR

NVST

NWSA

ODFL

ORLY

PAHC

PFGC

Earnings Scheduled For February 5, 2025

Accuray Says Shandong Cancer Hospital And Institute Achieved Completion Of Treatment For 100 Patients Using The Tomo C Radiation Treatment Delivery System

Accuray Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter.

Management

Accuray Announces Leonel Peralta Is Joining The Company As Senior Vice President, Chief Operations Officer, Effective February 3, 2025

Biotech

Accuray's Radixact SynC System And CyberKnife S7 System Have Been Approved By The Chinese National Medical Products Administration

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/01/2025-01-07_08h51_22.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Stay Ahead Of The Curve</h4>
An enlarged chart of NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of NVDA stock is being used to illustrate the point. As full disclosure, NVDA is in The Arora Report&#8217;s ZYX Buy Model Portfolio.</li>
<li>The chart shows NVDA stock is above the micro support zone.&nbsp; Previously, this was a resistance zone.</li>
<li>The chart shows that the move up has not been on heavy volume. This indicates a lack of conviction.</li>
<li>Nvidia's CEO Jensen Huang gave the keynote address at the Consumer Electronics Show (CES) yesterday evening.</li>
<li>The momo crowd ran up NVDA stock ahead of, during, and after Huang's presentation, pushing NVDA stock to a new all time high.</li>
<li>Here are the key points from Huang's presentation:
<ul>
<li>The ChatGPT moment for robotics is around the corner.</li>
<li>Nvidia plans to release a personal AI supercomputer for AI data scientists and researchers, so they do not need to connect to AI data centers.&nbsp; The personal AI supercomputer is called Project DIGITS and will have a Blackwell AI chip.</li>
<li>New Nvidia graphics chips for gamers will be available later this month.&nbsp; The chips leverage AI to enhance resolution and frame rates.</li>
<li>Nvidia will offer AI blueprints, making it easier to use AI agents for a variety of tasks such as generating blog posts and analyzing video.</li>
</ul>
</li>
<li>A fortune is to be made in AI all the way to 2030.&nbsp; It is not going to be in a straight line.&nbsp; At times it will be treacherous.&nbsp; It is important to build your investing knowledge in AI.&nbsp; The problem you face is that much of the information available about investing in AI is not objective and not in your best interest.</li>
<li>Total insanity is prevailing in robotics stocks.&nbsp; Robotics stock valuations have become totally divorced from reality.&nbsp; The momo crowd is in fantasy land and aggressively buying robotics stocks.&nbsp; Here are the top stocks in the Arora robotics basket: Symbotic Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>), Serve Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>), iRobot Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>), Myomo Inc (NYSEAMERICAN: MYO), Aurora Innovation Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>), Ouster Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>), Microbot Medical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>), Richtech Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RR#NASDAQ">RR</a>), Nauticus Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>), Arbe Robotics Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>), Kraken Robotics Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KRKNF#OTC">KRKNF</a>), Simpple Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPPL#NASDAQ">SPPL</a>), Lifeward Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>), Accuray Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>), and Guardforce AI Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFAI#NASDAQ">GFAI</a>).&nbsp; As full disclosure, there was a new signal on SYM given in The Arora Report&#8217;s ZYX Buy.</li>
<li>JOLTS job openings will be released at 10am ET and may be market moving.</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Microsoft Corp and NVDA.
In the early trade, money flows are neutral in Amazon.com, Inc. and Alphabet Inc Class C .
In the early trade, money flows are negative in Tesla Inc,  Apple Inc , and Meta Platforms Inc.
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust and Invesco QQQ Trust Series 1.
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust.  The most popular ETF for silver is iShares Silver Trust .  The most popular ETF for oil is United States Oil ETF.
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Trading Ideas

ARBE

GFAI

IRBT

KITT

KRKNF

LFWD

MBOT

NVDA

OUST

SERV

SPPL

ChatGPT Moment For Robotics Is Around The Corner Says Nvidia CEO

Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications

Accuray's CyberKnife System Offers Promising Outcomes For Brainstem Metastases, Highlighting Safety And Precision

<h3>Gainers</h3>
<ul>
<li>Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) shares rose 26.9% to $3.82 during Friday's pre-market session. The market value of their outstanding shares is at $186.6 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock increased by 19.74% to $0.39. The market value of their outstanding shares is at $6.4 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock rose 17.01% to $0.78. The company's market cap stands at $48.1 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock rose 14.44% to $1.03. The market value of their outstanding shares is at $4.6 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock increased by 12.84% to $1.23. The market value of their outstanding shares is at $10.7 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) shares rose 11.76% to $0.95. The company's market cap stands at $62.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Applied Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) stock fell 74.5% to $2.19 during Friday's pre-market session. The market value of their outstanding shares is at $254.8 million. </li>
<li>Journey Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>) stock declined by 13.52% to $4.8. The market value of their outstanding shares is at $100.2 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined by 12.64% to $7.05. The company's market cap stands at $4.7 billion. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock fell 12.38% to $4.25. The company's market cap stands at $47.1 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock declined by 10.37% to $0.54. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) shares declined by 9.96% to $1.9. The company's market cap stands at $191.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APLT

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BMRA

CABA

DERM

GRFS

IOBT

NTRB

PASG

SILO

TCBP

12 Health Care Stocks Moving In Friday's Pre-Market Session

Accuray Sees FY25 Total Revenue $462M-$472M

Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. The company reported quarterly sales of $101.500 million which beat the analyst consensus estimate of $97.552 million by 4.05 percent. This is a 2.30 percent decrease over sales of $103.892 million the same period last year.

Accuray Q1 2025 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $101.500M Beat $97.552M Estimate

The research builds on previously reported data and shows that at five years, stereotactic body radiation therapy (SBRT) provides comparable rates of cancer control, tolerability and sexual functioning to conventional radiotherapy (CRT), while reducing the overall treatment timeframe from up to 39 days of treatment to just five days. The Accuray <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4280414-1&amp;h=1067734035&amp;u=https%3A%2F%2Fwww.accuray.com%2Fcyberknife%2F&amp;a=CyberKnife">CyberKnife</a>&nbsp;System was used in the SBRT treated arm of the PACE-B study and showed excellent disease control with low rates of toxicity for men with prostate cancer.

Accuray Announced That Results Of The Pace-B– Prostate Advances In Comparative Evidence – Trial Were Published In The New England Journal Of Medicine

Offerings

Accuray's President And Chief Executive Officer Suzanne Winter To Take Temporary Medical Leave Of Absence; Sandeep Chalke Will Serve As Interim CEO During Winter's Absence

The new system is intended for emerging markets where access to advanced cancer care, including radiotherapy treatments, is typically obtainable only within urban areas and where the availability of linear accelerators per million population is well below the World Health Organization recommended guidelines.

Accuray Secures CE Mark For Accuray Helix, A CT-Guided Helical Radiotherapy System

Contracts

Press Releases

Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat

Accuray Announces China National Medical Products Administration Approval of the Radixact® SynC™ and CyberKnife® S7™ Systems; Expands on the China Product Portfolio that Includes the Recently Approved Tomo® C System

Leonel Peralta to Join Accuray as Chief Operations Officer

Accuray to Report Second Quarter Fiscal 2025 Financial Results on February 5, 2025

Accuray Announces First 100 Patient Treatment Regimens Completed in China Using the Tomo® C Radiation Treatment Delivery System, a CNNC-Accuray Joint Venture Product

Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

Accuray to Participate at 37th Annual Roth Conference

Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

Comments

Accuray

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO